Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

trans-Pralsetinib (Synonyms: trans-BLU-667)

Catalog No. T10823 Copy Product Info
Purity: 98.06%
🥰Excellent
trans-Pralsetinib (trans-BLU-667) is a potent inhibitor of the RET (Rearranged during Transfection) kinase. This compound originates from Compound Example 129 in patent US20170121312A1. RET is a receptor tyrosine kinase whose genetic rearrangements or mutations are key drivers in various cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer. By inhibiting RET kinase activity, trans-Pralsetinib blocks downstream oncogenic signaling pathways, thereby exerting anti-tumor effects.

trans-Pralsetinib

Copy Product Info
🥰Excellent
Catalog No. T10823
Synonyms trans-BLU-667

trans-Pralsetinib (trans-BLU-667) is a potent inhibitor of the RET (Rearranged during Transfection) kinase. This compound originates from Compound Example 129 in patent US20170121312A1. RET is a receptor tyrosine kinase whose genetic rearrangements or mutations are key drivers in various cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer. By inhibiting RET kinase activity, trans-Pralsetinib blocks downstream oncogenic signaling pathways, thereby exerting anti-tumor effects.

trans-Pralsetinib
Cas No. 2097132-93-7
Pack SizePriceUSA StockGlobal StockQuantity
2 mg$64-In Stock
1 mL x 10 mM (in DMSO)$297-10 days7-10 days
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.06%
Appearance:Viscous
Color:Transparent
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
trans-Pralsetinib (trans-BLU-667) is a potent inhibitor of the RET (Rearranged during Transfection) kinase. This compound originates from Compound Example 129 in patent US20170121312A1. RET is a receptor tyrosine kinase whose genetic rearrangements or mutations are key drivers in various cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer. By inhibiting RET kinase activity, trans-Pralsetinib blocks downstream oncogenic signaling pathways, thereby exerting anti-tumor effects.
Synonymstrans-BLU-667
Chemical Properties
Molecular Weight533.6
FormulaC27H32FN9O2
Cas No.2097132-93-7
SmilesC(N[C@@H](C)C=1C=CC(=NC1)N2N=CC(F)=C2)(=O)[C@]3(OC)CC[C@@H](CC3)C=4N=C(NC5=NNC(C)=C5)C=C(C)N4
Relative Density.1.40 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 80 mg/mL (149.93 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8741 mL9.3703 mL18.7406 mL93.7031 mL
5 mM0.3748 mL1.8741 mL3.7481 mL18.7406 mL
10 mM0.1874 mL0.9370 mL1.8741 mL9.3703 mL
20 mM0.0937 mL0.4685 mL0.9370 mL4.6852 mL
50 mM0.0375 mL0.1874 mL0.3748 mL1.8741 mL
100 mM0.0187 mL0.0937 mL0.1874 mL0.9370 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy trans-Pralsetinib | purchase trans-Pralsetinib | trans-Pralsetinib cost | order trans-Pralsetinib | trans-Pralsetinib chemical structure | trans-Pralsetinib formula | trans-Pralsetinib molecular weight